Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (“Titan”) announces that it has entered into a Merger and Contribution and Share Exchange Agreement (the “Merger Agreement”) regarding a business combination with KE Sdn. Bhd. (“KE”). Titan Pharmaceuticals, Inc. (NASDAQ: TTNP), based in South San Francisco, CA, is a development stage company previously focused on developing proprietary therapeutics utilizing ProNeura® long-term, continuous drug delivery technology. In December 2021, Titan commenced a process to explore and evaluate strategic alternatives to enhance shareholder value.
Read the full article: Titan Pharmaceuticals Enters into Merger Agreement with KE Sdn. Bhd. //
Source: https://www.globenewswire.com/news-release/2024/08/19/2932437/0/en/Titan-Pharmaceuticals-Enters-Into-Merger-Agreement-With-KE-Sdn-Bhd.html